Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 3

2(50.0%)

Phase 2

1(25.0%)

N/A

1(25.0%)

4Total

Phase 3(2)

Phase 2(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT03649503Recruiting

The National Registry Study For the Real-world Patients With Parkinsonian Disorders in China

Role: collaborator

NCT04067505Phase 3Recruiting

Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study

Role: collaborator

NCT04066764Phase 3Recruiting

Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters

Role: collaborator

NCT04086147Phase 2Completed

CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase

Role: collaborator

NCT02760953Not ApplicableUnknown

TURBt With Adjuvant Cryoablation to Treat Bladder Cancer

Role: collaborator

All 5 trials loaded